Hāʻawi iā Golda MV > Nā lāʻau lapaʻau

Loaʻa ka lāʻau lapaʻau ma ke ʻano o nā papa me kahi hoʻokuʻu i hoʻololi ʻia: keʻokeʻo a keʻokeʻo paha me kahi hāpana melemele, pōʻai, keliʻi-cylindrical, me kahi bevel, ma nā papa me ke ʻano he 60 mg ka loaʻa ʻana i kahi pilikia hoʻokaʻawale (no kahi ala o 30 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 180, 200 a 300 paha mau kekona i nā kēne, ma kahi pūlū pepa 1 hiki, 10 pcs i nā blisters, i loko o kahi pōpō kāleka i nā pālolo, he mau pā 60 mg: 10, 20, 25, 30, 40, 50, 60, 70, 75, 80, 84, 90, 100, 120, 125, 140, 150, 180, 250, a i ʻole 300 mau lōkē i loko o nā kaha, ma kahi pahu pepa. 1 hiki i loko o nā pā i loko: 10 pcs., Per nā pākeke pepa 1-10 mau pā, 7 pcs., a i ka pahu pahu 2, 4, 6, 8 a i ʻole 10 mau pūʻulu. Aia pū kēlā me kēia pūpū i nā ʻōlelo aʻoaʻo no ka hoʻohana ʻana iā Golda MV).

Pākaukau 1 papa:

mea waiwai: gliclazide - 30 a 60 mg,
ʻO nā mea kōkua: lactose monohydrate, sodium carboxymethyl starch (type C), hypromellose 2208, colloidal silicon dioxide, magnesium stearate.

Lapaʻau lāʻau

ʻO Golda MV kahi lāʻau lapaʻau hypoglycemic oral. ʻO Gliclazide, ʻo ia ka hana ikaika, he hoʻololi i hoʻokuʻu ʻia o ka sulfonylurea o ka lua o ka hanauna. Hoʻokaʻawale ʻia ia mai nā mea like ʻole e ka neʻe ʻana o kahi hā heterocyclic N-piha me ka mea paʻa endocyclic. Ke hoʻoulu nei ʻo Glyclazide i ka huni o ka insulin e nā beta beta o nā mokupuni o Langerhans, e hoʻoneʻe ana i ka kaila o ka glucose i ke koko. Ma hope o ʻelua mau makahiki o ka lapaʻau, hoʻomau ka hopena o ka hoʻonui ʻana i ka neʻe o ka insulin postprandial a me C-peptide.

Me ka hopena o nā pūkini momona, loaʻa iā ia kahi hopena hemovascular. Ma ke ʻano 2 diabetes mellitus, kōkua ka gliclazide e hoʻihoʻi i ka wanaʻao mua o ka huna ʻana o ka insulin i ka pane ʻana i ka hoʻokomo o glucose a hoʻonui i ka lua o ka hana huna o ka insulin. Hoʻonui nui ka mea huna a me ka hoʻonui ʻana ma ka hope o ka hoʻoulu ʻana ma muli o ka ʻai kai a me ka hoʻokele glucose.

Hōʻike ʻia nā hopena o hemovascular o gliclazide e ke kaemi iki o ka thrombosis kī liʻiliʻi. Hoʻopili iki kekahi i nā hōʻiliʻili o ka platelet a me ka hoʻopulapula, e hōʻemi i ka pae nui o ka hoʻonaninani ʻana i nā ʻano o nā platelet activation (thromboxane B2, beta-thromboglobulin). Kōkua i ka hoʻonui i ka hana o nā kiko plasminogen kiko, i ka hopena ma ka hoʻihoʻi ʻana o ka hana fibrinolytic o ka votoma endothelium.

I nā maʻi me ka hemoglobin glycemic (Hb_A1c) ma mua o 6,5%, ka hoʻohana ʻana o gliclazide e hāʻawi i ka mana glycemic intensive, hoʻemi nui loa i nā hoʻopiʻi micro- a me ka macro-vascular o ka maʻi type 2.

Ke kumu o ka gliclazide no ka manaʻo o ka mana glycemic control pili i ka hoʻonui ʻana i kona mahele i hui pū ʻia me ka maʻi maʻamau (a i ʻole ʻo ia ma mua) i ka hoʻohui ʻana i ka metformin, kahi deriaative thiazolidinedione, he mea hoʻomehana alpha-glucosidase, insulin a i ʻole nā hāmeʻa hypoglycemic hou iā ia. Ua hōʻike ʻia nā hualoaʻa o nā noiʻi maʻi ma mua, e pili ana i ka mua o ka hoʻohana ʻana o gliclazide i ka awelika o kēlā me kēia lā he 103 mg (nui loa ka nui o 120 mg), ka hopena pālua o ka hoʻopili hoʻohui o nā macro- a me nā hoʻopiʻi microvascular he 10% haʻahaʻa ma mua o ke ʻano hoʻokele maʻamau.

ʻO ka maikaʻi o ke kahe glycemic intensive ke lawe aku nei i ka Golda MV me ka hōʻemi nui o ka hōʻeha ʻana i nā hōʻeha o nā pathologies e like me nā mikumoku nui (ma ka 14%), nephropathy (e ka 21%), nā hoʻopiha renal (ma 11%), microalbuminuria (e 9%) , macroalbuminuria (30%).

Lapaʻau lāʻau

Ma hope o ka lawe ʻia ʻana o ka Golda MV, ua hoʻopili pono ʻia ka glycazide, piʻi mālie kona pae plasma a hiki i ka pāpū i loko o 612 mau hola. ʻAʻole pili ka ʻai i ka ʻai me ke kūlohelohe o ka nalo ʻana, ʻokoʻa ke ʻano like o kēlā me kēia. ʻO ka Gliclazide i kahi pāʻina a hiki i ka 120 mg ka hōʻailona i ka pilina laina ma waena o ka hopena i kā ʻia ʻia a me AUC (ʻo ka wahi ma lalo o ka pihi pharmacokinetic kuʻina i ka manawa).

Hoʻohālikelike i nā protein plasma koko - 95%.

ʻO ka nui o ka hoʻoili e pili ana i 30 litela. ʻO hoʻokahi kaona hoʻokahi o ka gliclazide e hōʻoia i ka mālama pono ʻana o ka plasma koko i mālama ʻia ma mua o 24 mau hola.

Hoʻopili ʻia ka Gliclazide i ka nui o ka ate. ʻAʻole ola kekahi mau metabolites ma loko o ke koko koko.

ʻO ka hoʻopau hapa hapalua-ola he 12-20 hola.

Hoʻokuʻu ʻia ia ma o nā maʻamau ma o ke ake o ke ʻano o ka metabolites, i loli ʻole - ma lalo o 1%.

I nā poʻe maʻi maʻi, ʻaʻole i manaʻo ʻia nā loli nui i ka lāʻau pharmacokinetic.

Nā hōʻailona no ka hoʻohana ʻana

ka mālama ʻia ʻana o ka maʻi mellitus type 2 - i ka ʻole o ka lawa o ka hopena o ka mālama ʻana i ka meaʻai, ka hana kino a me ke kaumaha.
ka pale ʻana o nā hoʻopiʻi ma ka poʻe maʻi me ka maʻi diabetes mellitus type 2 - hōʻemi i ka hōʻemi o ka microvascular (retinopathy, nephropathy) a me ka macrovascular (myocardial infarction, stroke) mau ala ma waena o ka mana glycemic control.

Nā Hoʻohui

maʻi diabetes type 1
diabetic precoma, diabetes coma,
maʻi maʻamau ketoacidosis,
pilikia hōʻeha loa,
uhaiki ikaika
hui pū me ka miconazole,
hui pū me ka danazol a i ʻole phenylbutazone,
congolole lactose intolerance, galactosemia, glucose-galactose malabsorption,
wā hāpai
hana waiū
makahiki i 18 makahiki
intolerance kanaka i derivatives sulfonylurea, sulfonamides,
hypersensitivity i nā ʻāpana o ka lāʻau.

Pono e hoʻohana ʻia nā papa gula gula me ka akahele i nā poʻe maʻi me nā mea ʻole aʻai ʻole a i ʻole ke hoʻoponopono ʻia, nā maʻi koʻikoʻi o ka ʻōnaehana cardiovascular (maʻi ʻeha coronary koʻikoʻi, nui atherosclerosis, arteriosclerosis nui), glucose-6-phosphate dehydrogenase poʻokela, renal a / a i ʻole ake kaulike, adrenal a pituitary insufficiency, hypothyroidism, longed therapy a glucocorticosteroids (GCS), ʻalowa.

ʻO Golda MV, ke kauoha no ka hoʻohana ʻana: ke ʻano a me ka helu ʻana

Lawe ʻia nā papa gula gula maʻamau, ʻūlū piha (me ka ʻole o ka honi), ʻoi loa i ka wā kakahiaka.

Kahi ʻia ka lā ma kēlā me kēia lā a pono i waena o ka 30 a me ka 120 mg.

ʻAʻole hiki iā ʻoe ke hōʻeha me ka nalowale i hala i ke ʻano aʻe ma ke ʻano he aʻe, e loaʻa ana he nui ka nui.

Koho ʻia ka helu o ka gliclazide i kēlā me kēia kanaka, i ke ʻano o ka nui o ka glucose i loko o ke koko a me ka māka Hb_A1c.

Ke koho ʻia nei: ʻo ka inika mua loa he 30 mg (1 papa gula Gold MV 30 mg a i ½ papa gula MV 60 mg). Inā hāʻawi ʻia ka lāʻau i kuhikuhi ʻia e ka lawa glycemic kūpono, a laila hiki ke hoʻohana ʻia ia e like me ka mālama mālama ʻana. I ka hana ʻole ʻana i kahi hopena lapaʻau kūpono ma hope o nā lā 30 o ka lapaʻau, ʻoi ka hoʻonui mua ʻana o ka nui o nā piʻi me 30 mg (a hiki i 60, 90, 120 mg). I nā hihia kūʻokoʻa loa, inā ʻaʻole i emi ka pae o ke koko o ka mea maʻi ma hope o nā lā 14 o ka lapaʻau, hiki iā ʻoe ke hoʻomau i ka nui o ka 14 i nā lā ma hope o ka hoʻomaka ʻana o ka hoʻokō.

ʻO ka dosis kiʻekiʻe loa i kēlā me kēia lā he 120 mg.

Ke hoʻololi nei mai ka lawe ʻana i nā papa glyclazide koke i ka nui o ka 80 mg, e hoʻomaka me nā papa hoʻokuʻu i hoʻololi ʻia e hoʻomaka me ka pae o 30 mg, ka hoʻomohala ʻana me ka mālama ʻana me ka mālama glycemic maikaʻi.

Ke hoʻololi nei i Golda MV me nā lāʻau lapaʻau hypoglycemic ʻē aʻe, ʻaʻole pono kahi manawa hoʻololi. ʻO ka maʻa mua o gliclazide i nā papa hoʻokuʻu i hoʻololi ʻia e pono 30 mg, ukali ʻia e ka titration ma muli o ke kaʻe o ka glucose i loko o ke koko.

I ka unuhi ʻana, pono ka mālama ʻia ʻana o ka lāʻau a me nā hapalua o ka lāʻau hypoglycemic ma mua. Inā loli ka pili o sulfonylurea me kahi hapalua lōʻihi, a laila hiki ke kāpaeʻia nā āpau hypoglycemic āpau no kekahi mau lā. Hōʻalo kēia i ka hypoglycemia ma muli o ka hopena hoʻohui o ka glycoslazide a me nā wanana o ka sulfonylurea.

Ua hōʻike ʻia ka hoʻohana ʻana o Golda MV i ka hui pū me nā alpha-glucosidase inhibitors, biguanides a i ʻole insulin.

ʻAʻole pono nā poʻe maʻi (ʻoi aku ma mua o 65) e hoʻoponopono ʻia.

I ka maʻalahi o ka hoʻololi ʻole ʻana i ka hopena, ʻaʻole pono ke hoʻoponopono ʻia.

Manaʻo ʻia e hoʻohana i kahi palena liʻiliʻi (30 mg) o ka lōʻihi o ka hana gliclazide no ka mālamaʻana i nā mea maʻi i ka pilikia o ka hoʻomohala ʻana i ka hypoglycemia, kahi pāʻina kūlike ʻole a i ʻole ke kaupaona ʻana, ka maʻi hoʻokaumaha a ʻole hoʻokalakupua ʻole, ka maʻi hypothyroidism, nā maʻi koʻikoʻi o ka system cardiovascular, ka manawa ma hope o ka manawa lōʻihi a me / a i ʻole ka hoʻoponopono ʻana i nā maʻi kiʻekiʻe. glucocorticosteroids (GCS).

ʻO ka hoʻohana ʻana o Golda MV ma kahi o ka meaʻai a me ka hana e pale ai i nā hoʻopiʻi o ka maʻi type 2 e hoʻomaka e hoʻomaka me kahi hapa o 30 mg. E hoʻokō i ka mana glycemic koʻikoʻi a me nā pae Hb_A1c hiki ke hoʻonui ikaika ʻia ka paona mua i kahi kiʻekiʻe loa o 120 mg i kēlā me kēia lā. Ke hōʻike nei ke kumu o ka lāʻau no ka control glycemic intensive me ka hoʻohui me ka metformin, kahi alpha-glucosidase inhibitor, kahi thiazolidinedione derivative, insulin a me nā mea hana hypoglycemic āpau.

Nā hopena hopena

Me nā hana o ka ʻai ʻai a i ʻole ka launa ʻole ʻōnaehana ʻole, ʻike ʻia nā huaʻōlelo ma lalo o ka hypoglycemia: nui ka momona, ka pōloli nui, hōʻeha, hōʻeha, hoʻāla, hoʻohuihui, hoʻāhu, hoʻoneʻe, hōʻeha, nāwaliwali, hilahila hiamoe, irritability, ʻūhā, haunaele, ke kaumaha, ʻike ʻole ʻia a me ka haʻi ʻana, ka paresis, aphasia, nui, ka nalowale ʻana o ka ʻike pono ʻole, ka manaʻo hopohopo, ʻike ʻole ʻana i ka hopohopo, nā kuhi, ka wā papau, bradycardia, delirium, ka hiamoe st, lilo o ka ike paka i, coma (me ona e), adrenergic muli o - mahuahua sweating, uunu nui, clammy ili o ke kino, tachycardia, mahuahua ke koko, (ke koko,), arrhythmia, palpitations, angina pectoris. Hōʻike nā hualoaʻa o nā noiʻi maʻi ma ke ke hoʻohana ʻana i ka lāʻau lapaʻau no ka mālama ʻana i ke ʻano glycemic intensive, hele pinepine ka hypoglycemia ma mua o ka mana glycemic control. ʻO ka hapa nui o ka hypoglycemia ma ke kuʻina hanana glycemic intensive ka mea i kū i ke kua o ka concomitant insulin therapy.

Eia kekahi, kūʻē i ka ʻikepili o ka hoʻohana ʻana o Golda MV, hiki i ke ʻano aʻe nā hopena kūpono:

mai ka ʻeha o ka gastrointestinal: ʻeha o ka ʻōpū, ke kuʻuna, ka luaʻi, ka ʻōpū ʻana o ka ʻōpū, ka constipation
mai nā mea lymphatic a me ke kaila: jarang - thrombocytopenia, anemia, leukopenia, granulocytopenia,
mai ka ʻōnaehana hepatobiliary: hana nui o ka phosphatase alkaline, ACT (aspartate aminotransferase), ALT (alanine aminotransferase), hepatitis, jaundice cholestatic,
ma ka ʻaoʻao o ke kino o ka hihiʻo: nā mea iʻike pinepine ʻia (i nā manawa pinepine ma ka hoʻomaka ʻana o ka hoʻōla),
nā hana dermatological: itching, pāheʻe, maculopapular rash, urticaria, erythema, edema Quincke, mau hopena bullous (me ke ʻano o Stevens-Johnson syndrome, ua hoʻopaʻa ʻia ka necrolysis epidermal).
ʻokoʻa (nā hopena hopena i ʻike ʻia i nā derivatives sulfonylurea): hemolytic anemia, erythrocytopenia, agranulocytosis, allergic vasculitis, pancytopenia, hyponatremia, jaundice, hōʻeha pū ka ʻeha.

Ke keu

Nā hōʻailona: me kahi overdose, hōʻailona mau i ka hōʻailona o ka hypoglycemia.

Hoʻomaʻamaʻa: e hoʻopau i nā hōʻailona maʻalahi o hypoglycemia (me ka ʻole o ka hōʻailona neurological a me ka ʻike ʻole ʻole ʻia), pono e hoʻonui i ka ʻai paʻakai, e hoʻemi i ka ʻaiʻī o Golda MV a / a hoʻololi i ka ʻai. Hōʻike ʻia ka mālama mālama ʻana i ke kūlana o ka mea maʻi.

Me ke ʻano o nā kūlana hypoglycemic koʻikoʻi (coma, koi a me nā pilikia ʻē aʻe o ka neʻe ʻana mai o ka neurological), koi koke ʻia ka hoʻokipa maʻi.

ʻO ka mālama maʻi olakino no ka hōʻeha o ka hypoglycemic coma a i ʻole kānalua ia e pili ana i ka hoʻonā ʻana i ka intravenous (iv) o ka hoʻonā ʻana i ka hopena o 20-30% dextrose (glucose) i kahi paena o 50 ml, e ukali ʻia e ka wai drip o 10% dextrose solution, ka mea e mālama ai i ke pae o ka mālama glucose i koko i luna o 1 g / l. Mālama ka mālama pono ʻana i ke kūlana o ka mea maʻi a me ka nānā pono ʻana i ka kaohi koko o kaʻelima e hoʻomau ʻia no nā hola 48 e hiki mai.

ʻAʻohe kūpono ʻo Dialysis.

Nā ʻōlelo kikoʻī

Pono ke kaupaona ʻana ʻo Golda MV inā he ʻai nā mea ʻai i ka ʻaina kakahiaka, a maʻa mau ka meaʻai. Hoʻopili ʻia kēia me ka hopena kiʻekiʻe o ka hiki ʻana o ka hypoglycemia, me ka loaʻa ʻole o ka lōʻihi a me ka lōʻihi o ka hoʻopiʻi ʻana i koi i ka hoʻokipa a me ka mālama ʻana iv o kahi hopena dextrose no kekahi mau lā. I ka wā o kahi hoʻokomo o Golda MV, he mea nui loa ia e hōʻoia i kahi lawa o ka nui o nā hāmeʻa i loko o ke kino me ka meaʻai. ʻO kaʻai maʻamau, ʻaʻole kaʻai kīnā, a i ʻole nā meaʻai i kālaiʻaka waiwai ke alakaʻi i ka hypoglycemia. ʻOi aku ka pinepine o ka hoʻomohala ʻana o ka hypoglycemia i ka poʻe maʻi e hahai ana i ka lāʻau o ka laiki haʻahaʻa, ma hope o ka ikaika a lōʻihi paha ka hoʻoikaika ʻana, inu wai inu, a i ʻole e mālama ʻana me kekahi mau mea maʻi hypoglycemic i ka manawa like. ʻO ka maʻamau, ʻo ka meaʻai me nā momona o ka kalaiwa (me ke kōpala) hiki ke kōkua i ka hōʻemi o nā hōʻailona o ka hypoglycemia. I kēia hihia, ʻaʻole maikaʻi ka hoʻohana ʻana o ke kō. Pono e noʻonoʻo i ka hypoglycemia hiki ke hana hou. No laila, inā ua hypoglycemia kahi i hōʻike i ka hōʻailonaatology a i ʻole ke lōʻihi o ka manawa, ʻoiai ka hopena o ka lawe ʻana i nā meaʻai momona, pono ʻoe e ʻimi i ke kōkua olakino pōpilikia.

Ke koho nei iā Golda MV, pono ke kauka e hōʻike i ka mea maʻi i ka kikoʻī e pili ana i ka lāʻau lapaʻau a me ka pono o ka hoʻokō koʻikoʻi i ka regimen dosing, kahi meaʻai kūʻai a me ka hana kino.

ʻO ke kumu o ka hoʻomohala ʻana o ka hypoglycemia, ʻo ka hiki ʻole o ka mea maʻi a makemake ʻole (ʻoi loa hoʻi i ka wā kahiko) e hahai i nā ʻōlelo a ke kauka a me ka hoʻomohala ʻana i nā honu koko, lawa ʻole nā mākeke, ka hoʻololi ʻana i ka ʻai, ka ʻoki ʻana i ka ʻai a me ka pōloli, ʻokoʻa ʻole ma waena o ka hana kino a me ka nui o nā kākeka i lawe ʻia , ka maikaʻi ʻole o ka hana ʻana i ka lāʻau, overdose drug, pituitary a me adrenal insufficiency a / ai ʻole ka maʻi thyroid.

Eia kekahi, hiki i ka hypoglycemia ke kāpili i ka pilina o gliclazide me nā lāʻau lapaʻau concomitant. No laila, pono ka mea maʻi e ʻae me kekahi kauka i ka lawe ʻana i kekahi lāʻau lapaʻau.

Ke koho nei iā Golda MV, pono ke kauka e hōʻike i ka mea maʻi a me kona ʻohana i nā kikoʻī e pili ana i nā hōʻeha a me nā pōmaikaʻi o ka hanana e hiki mai ana, nā kumu a me nā hōʻailona o ka hypoglycemia, ka mea nui o ka hahai ʻana i ka meaʻai i makemake ʻia a me kahi hoʻonohonoho o ka hana pilikino, ke aʻo ʻana i ka mālama mau o ka mālama pono ʻana i ke kaʻe o ka glucose koko.

I mea e loiloi ai i ka kontrol glycemic, pono e hoʻopaʻa ʻia ʻo Hb i nā manawa a pau._Alc.

Pono e hāpai i ka maʻi me ka hepatic concomitant a me / a i ʻole ka hopena ʻole o ka renal i hiki ke lōʻihi ka lōʻihi o ke kūlana hypoglycemia, a koi koke i ka mālama kūpono.

ʻO ka hopena i loaʻa iā glycemic hiki ke palupalu i ka hopena o ke ʻano o ka maʻi o ka maʻi, nā maʻi ʻeha, nā hōʻeha a me nā mea hoʻoweliweli ākea. I kēia mau kūlana, ʻōlelo ʻia e ka hoʻololi i ka mea maʻi i ka hoʻomehana ʻana i ka insulin.

ʻO ka nele o ka maikaʻi o ka gliclazide ma hope o ka lōʻihi o ka mālama ʻana ma muli o ke kūleʻa o ka lāʻau kūlohelohe, ʻo ia kahi hopena o ka piʻi ʻana o ka maʻi a hoʻohemo paha i ka pane lāʻau lapaʻau i ka lāʻau. Ke hōʻike nei i ka pale ʻana o ka lāʻau lapaʻau kūloko, pono e hōʻoia i ka mea e pili ana ka mea maʻi i ka meaʻai i wae ʻia a loiloi i ka lawa o ka hopena o ka nui o kā Golda MV i lawe ʻia.

Me ka nele o ka dehydrogenase glucose-6-phosphate, ʻo ka hoʻohana nui ʻana o nā derivatives sulfonylurea e hoʻonui i ka hopena o ka anemia hemolytic. No laila, no ka mālamaʻana i nā poʻe maʻi me ka nele o ka glucose-6-phosphate dehydrogenase, nā mākaʻi hypoglycemic o kekahi hui ʻē aʻe.

Hoʻohui nūhou

miconazole: ʻōnaehana o ka miconazole a i ʻole ka hoʻohana ʻana i ke ʻano o ka gel ma ka mucosa waha e hoʻopiʻi ai i ka hopena o ka hypoglycemic hopena o gliclazide, kahi e hiki ai i ka hoʻomohala ʻana o ka hypoglycemia a hiki i kahi coma.
phenylbutazone: hui pū me nā waha waha phenylbutazone e hoʻomaikaʻi i ka hopena hypoglycemic o Golda MV, no laila, inā hiki ʻole ke kuhikuhi i kekahi lāʻau lapaʻau anti-inflammatory, pono ia e hoʻoponopono i ke ʻano o ka glyclazide ʻelua i ka wā o ka hoʻokō o phenylbutazone a ma hope o kona wehe ʻia ʻana,
ka hopena: ka hoʻohana ʻana o nā mea inu ʻawaʻī a i ʻole nā mea pono e manaʻo ʻia ka etanol i ke ʻano o ka hoʻoneʻeneʻe, e hiki ai iā ia ke hoʻonui i ka hypoglycemia a i ʻole ka hoʻomohala ʻana i ka comog hypoglycemic,
nā kumuhana hypoglycemic ʻē aʻe (insulin, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists), beta-blockers, fluconazole, angiotensin e hoʻohuli ana i ka hoʻohui o nā enzyme (blocking agents, enaprilap)₂-histamine receptors, monoamine oxidase inhibitors, sulfonamides, clarithromycin, non-steroidal anti-inflammatory drugs: ka hui pū ʻana o kēia mau lāʻau me ka glycazide i hui pū ʻia e ka hoʻonui ʻana o ka hana a Golda MV a me ka hoʻonui nui aʻe o ka ʻatikala o hypoglycemia,
danazol: ka hopena o ka maʻi maʻi maʻi o ka danazol e hoʻonāwaliwali i ka hana o gliclazide,
chlorpromazine: nā koina nui kiʻekiʻe o kēlā me kēia lā (ma mua o 100 mg) o ka chlorpromazine i hōʻemi ʻia i ka huna ʻana i ka insulin, e kōkua ana i ka hoʻonui ʻana o ka hoʻoliʻiliʻi glucose. No laila, me ka hoʻonaninani antipsychotic concomitant, ke koho ʻana i kahi pānena o kahi gliclazide a me ka mālama glycemic mālama, me ka waiho ʻana ma hope o ka hoʻokuʻu ʻana o ka chlorpromazine, e koi ʻia.
tetracosactide, GCS no ka hoʻohana ʻana i ka systemic a me ka topical hoʻohana: hoʻemi i ka hoʻokaʻawale kalama, e hāʻawi i ka hoʻonui i ka glycemia a me ka pilikia o ka hoʻomohala i ka ketoacidosis. E mālama ʻia ka mālama ʻana i ke kō o ka glucose koko, inā paha i ka hoʻomaka ʻana o ka hui pū ʻana, inā pono, hoʻonā ʻia nā dosis o gliclazide,
ritodrin, salbutamol, terbutaline (iv): pono e hoʻomaopopo ʻia he beta₂-adrenomimetics hoʻonui i ka kiʻekiʻe o ka glucose i loko o ke koko, no laila, i ka hui pū ʻana me lākou, pono ka poʻe maʻi i ka make glycemic self-control, hiki ke hoʻololi i ka mea maʻi i ka insulin lapaʻau,
warfarin a me nā mea anticoagulants: hiki i ka gliclazide ke hāʻawi i kahi hoʻonui nui i ka maʻi i ka hopena o nā anticoagulants.

ʻO nā ʻāpana o Golda MV nā: Diabetalong, Glidiab, Gliclada, Gliclazide Canon, Gliclazide MV, Gliclazide-SZ, Gliclazide-Akos, Diabeton MB, Diabinax, Diabefarm, Diabefarm MV, etc.

Hōʻikeʻike e pili ana i Gold MV

Hōʻikeʻike nā loiloi e pili ana i ka Gold MV. ʻO nā mea maʻi (a i ko lākou mau hoahānau paha) hōʻike i ka wikiwiki o ka loaʻa ʻana o ka nui o ke kō me ka hoʻohaʻahaʻa i ka lāʻau, ʻoiai he nui ka hopena o ka hypoglycemia a me nā hopena ʻē aʻe. Eia kekahi, ʻo ka hele ʻana o contraindications e manaʻo ʻia he mea hōʻeha.

I ka wā o ka hoʻokele ʻana o Golda MV, ua ʻōlelo ʻia e mālama pololei i ka meaʻai a me ka meaʻai, i kēlā lā i kēia lā, ka mālama koko koko.